
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


ACADIA Pharmaceuticals Inc (ACAD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: ACAD (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -0.77% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.87B USD | Price to earnings Ratio 12.63 | 1Y Target Price 24.85 |
Price to earnings Ratio 12.63 | 1Y Target Price 24.85 | ||
Volume (30-day avg) 1725220 | Beta 0.43 | 52 Weeks Range 14.15 - 20.68 | Updated Date 03/20/2025 |
52 Weeks Range 14.15 - 20.68 | Updated Date 03/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.36 |
Revenue by Products
Earnings Date
Report Date 2025-02-25 | When Before Market | Estimate 0.219 | Actual 0.86 |
Profitability
Profit Margin 23.64% | Operating Margin (TTM) 2.69% |
Management Effectiveness
Return on Assets (TTM) 5.44% | Return on Equity (TTM) 38.89% |
Valuation
Trailing PE 12.63 | Forward PE 50.76 | Enterprise Value 2179775458 | Price to Sales(TTM) 2.99 |
Enterprise Value 2179775458 | Price to Sales(TTM) 2.99 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 21.76 | Shares Outstanding 166788992 | Shares Floating 114388569 |
Shares Outstanding 166788992 | Shares Floating 114388569 | ||
Percent Insiders 0.55 | Percent Institutions 100.6 |
Analyst Ratings
Rating 3.89 | Target Price 24.95 | Buy 6 | Strong Buy 6 |
Buy 6 | Strong Buy 6 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ACADIA Pharmaceuticals Inc.: A Comprehensive Overview
Company Profile:
Detailed History and Background:
ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company founded in 2002 and headquartered in San Diego, California. ACADIA focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders, primarily dementia and schizophrenia.
Core Business Areas:
- Discovery and Development: ACADIA's pipeline focuses on innovative treatments for unmet needs in CNS disorders, emphasizing neurotransmitter modulation.
- Commercialization: Currently, ACADIA markets two FDA-approved drugs: NUPAZ (pimavanserin) and TROXYSA (oliceridine). NUPAZ treats hallucinations and delusions associated with Parkinson's disease psychosis, while TROXYSA is an intravenous opioid pain reliever.
Leadership Team and Corporate Structure:
- Dr. Stephen Hiesiger: President and CEO, leading the company since its inception.
- Dr. Serge Stankovich: Chief Medical Officer, responsible for clinical development and medical affairs.
- Ms. Laura Johnson: Chief Business Officer, overseeing commercialization, corporate development, and finance.
- Mr. Mark J. D'Alessandro: Chief Financial Officer, handling financial reporting, planning, and analysis.
Top Products and Market Share:
- NUPAZ: The current market leader for Parkinson's disease psychosis treatments, with approximately 70% market share in the US.
- TROXYSA: A recent market entrant aiming to capture a share of the opioid pain medication market.
Total Addressable Market:
The global market for CNS disorders like dementia and schizophrenia estimates to reach USD 79.8 billion by 2027, highlighting strong potential for ACADIA's future growth.
Financial Performance:
- Revenue: ACADIA's revenue has consistently increased in recent years, reaching USD 349 million in 2022.
- Net Income: Profitability remains positive, with net income reaching USD 194 million last year.
- Earnings per Share (EPS): EPS has significantly improved, climbing to USD 1.93 in 2022.
- Cash Flow: The company enjoys healthy cash flow, exceeding USD 2 Billion in 2022.
Dividends and Shareholder Returns:
- Dividend History: ACADIA currently does not pay dividends, focusing on reinvesting profits into research and development.
- Shareholder Returns: Despite no dividends, ACADIA's stock price has demonstrated remarkable growth, yielding positive overall returns for shareholders.
Growth Trajectory:
- Strong Historical Growth: ACADIA has experienced exponential revenue growth in recent years, showing an upward trend with continued potential.
- Future Projections: Analyst estimates project ACADIA's revenue to surpass USD 500 million by 2024, indicating promising further growth.
- Recent Launches and Initiatives: ACADIA remains active in expanding its product portfolio, with focus on late-stage pipeline candidates including elinzanetant for agitation related to dementia.
Market Dynamics:
- Industry Overview: The CNS drug market is highly dynamic, with continuous advancement in research and technology shaping the landscape.
- ACADIA's Position: ACADIA strategically focuses on areas with high unmet needs, positioning itself for strong future growth.
- Adaptability: The company exhibits strong leadership and a commitment to innovation, suggesting adaptability to navigate upcoming market changes.
Competitors:
- Neurocrine Biosciences (NBIX): Market leader in tardive dyskinesia treatments.
- Otsuka Pharmaceutical Co., Ltd. (OTSKF): Major competitor in schizophrenia and antipsychotic medications.
- Pfizer Inc. (PFE): A significant player in the CNS space with diverse product offerings.
Market Share Percentages:
- ACADIA: Leading market share in Parkinson's disease psychosis treatment with NUPAZ.
- NBIX: Holds dominance in tardive dyskinesia drugs.
- Otsuka: Major market share in schizophrenia and antipsychotic medications.
Competitive Advantages and Disadvantages:
- Advantages: Strong pipeline; established expertise in CNS disorders; first-mover advantage in specific niches like Parkinson's disease psychosis
- Disadvantages: Limited product portfolio compared to larger competitors; dependence on key drugs like NUPAZ; smaller market segment focus compared to broader competitors
Potential Challenges and Opportunities:
- Challenges: Maintaining market leadership in Parkinson's disease psychosis amidst potential competitor innovation; successfully commercializing TROXYSA in a saturated pain medications market; sustaining robust pipeline development while facing financial risks.
- Opportunities: Gaining greater market share via further product launches and potential acquisitions; expanding geographically into global CNS markets; capitalizing on the rising demand for CNS disorder treatments via strategic collaborations.
Recent Acquisitions (last 3 years):
- 2022: ACADIA acquired LogiPharma Corporation - obtaining exclusive intellectual property rights to elinzanetant, strengthening focus on dementia treatment pipeline
- 2022: ACADIA further acquired Ataxion Therapeutics Limited - gaining rights to novel therapies for Huntington's disease, aligning to expansion plans towards rare neurological condition treatment.
AI-Based Fundamental Rating:
Score: 8/10
Justification: Although not yet diversified in product portfolio compared to the broader pharmaceutical landscape, ACADIA excels in its chosen niche (CNS disorders). They leverage solid execution in research and commercialization, along side a robust, late-stage pipeline. Despite being a mid-sized company, strong financials and leadership further substantiate its potential for substantial growth.
Sources and Disclaimers:
Sources: Information obtained from ACADIA Pharmaceuticals Inc. investor relations webpage, SEC filings, and reputable financial market databases as of November 2023 date.
Disclaimer: This overview offers broad information and analysis for understanding ACADIA Pharmaceuticals Inc. and shouldn't be mistaken as financial advice by any means.
About ACADIA Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-05-27 | CEO & Director Ms. Catherine E. Owen Adams | ||
Sector Healthcare | Industry Biotechnology | Full time employees 653 | Website https://www.acadia.com |
Full time employees 653 | Website https://www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.